Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Study Overview The study aimed to evaluate the effectiveness and safety of mirikizumab, a monoclonal antibody targeting the IL-23 pathway, […]
